Phase I study of definitive CRT with paclitaxel, CDDP and 5-FU for clinical stage IA-IIIC esophageal cancer.(PCF-RT)
- Conditions
- Esophageal cancer
- Registration Number
- JPRN-jRCTs051180082
- Lead Sponsor
- Yamamoto Sachiko
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 24
1) Histologically proven squamous cell carcinoma, or adenosquamous cell carcinoma or basaloid of the esophagus
2) Primary lesion are located within the cervical esophagus (Ce) and the abdominal esophagus (Ae)
3) Aged 20 to 75 years old
4) ECOG PS of 0 or 1
5) Clinical stage IA - IIIC
6) No need for measurable lesion
7) No previous treatment of esophageal cancer except endoscopic surgery
8) No palsy of recurrent nerve
9) No adaptation of surgery or refused esophagectomy
10) Adequate organ functions
11) Written informed consent
1) Simultaneous or metachronous double cancers, with the exception of tumor curable with therapy before diagnosis of esophageal cancer or expected cure in surgery
2) history of radiotherapy for mediastinum
3) Uncontrollable diabetes mellitus
4) History of myocardial infarction within 6 months, or unstable angina pectoris or cardiac function disorder
5) Uncontrollable arrhythmia
6) Patients requiring systemic steroids medication
7) Liver cirrhosis
8) Active bacterial or fungous infection
9) With a history of grade 2-4 allergic reaction by CTCAE version 4.0
10) With a history of grade 2-4 nerve disturbance by CTCAE version 4.0
11) With blood transfusion within 2weeks and/or active bleeding
12) Interstitial pneumonia, fibroid lung or severe emphysema
13) With a history of allergic reaction to platinum, polyoxy-ethilen oil, hydrogenated castor oil or polysorbate 80
14) Psychosis
15) Pregnant or lactating women, women of childbearing potential or men who like to have children in future
16) Any patients judged by the investigator to be unfit to participate in the study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method